Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue
Corroborated by 1 source from 1 publisher
globalbusiness1d ago
TL;DR
According to finance.yahoo.com, faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio, Inc (NASDAQ:GOSS) commented: “Following our PROSERA topline results, we are focused on fully understanding the PROSERA dataset, engaging with the FDA, and evaluating strategic options and capital allocation to position the Company for the future.